In 2009, Zinzino Nordic AB was acquired partly through a directed share issue to shareholders in Zinzino Nordic AB and partly through a subscription of shares in the preferential rights issue Zinzino Nordic AB carried out in December 2009. This gave Zinzino AB control over 97% of the votes and 92% of the capital in Zinzino Nordic AB. Up to December 31, 2014, ownership increased to 93%.
Zinzino AB’s business operations began in the fall of 2007. The principal activity of the company is to own and develop companies within direct marketing and related business activities.
Dag Bergheim Pettersen
Business Development / CCO
MD Faun Pharma